AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02429414 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video Double Lumen Tube (VDLT)
Description: Participant receives video double lumen tube (VDLT) placement before surgery.
Study NCT00849732 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V520
Description: Intentionally Blank
Study NCT03535727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: IV over 30 minutes; Days 4 and 11
Study NCT03535727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV over 30 minutes; Days 4 and 11
Study NCT03535727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: PO BID; Days 1- 14
Study NCT03535727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV over 60 minutes; Days 4 and 11
Study NCT00849732 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: V520 (1x10^9 vp/d)
Description: 1.0 mL intramuscular injection of MRKAd5 HIV-1 gag vaccine at 1x10\^9 vp/d given at Day 1, Week 4, and Week 26
Study NCT00849732 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: V520 (1x10^10 vp/d)
Description: 1.0 mL intramuscular injection of MRKAd5 HIV-1 gag vaccine at 1x10\^10 vp/d given at Day 1, Week 4, and Week 26
Study NCT00849732 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo to MRKAd5 HIV-1 gag vaccine 1.0 mL intramuscular injection given at Day 1, Week 4, and Week 26
Study NCT03825770 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The PEP (Personal Energy Planning) Program
Description: The PEP program is designed to teach people on dialysis with fatigue how to conserve energy during day-to-day tasks, and how to use energy conservation to accomplish their goals. The program is delivered over 7-9 weekly sessions. It consists of 2 educational web modules about energy conservation, and 5-7 goal-focused training sessions with a study clinician that utilize a problem-solving training approach known as the Cognitive Orientation to Occupational Performance (CO-OP) approach. Each program session lasts \~20-30 mins. Sessions are completed either in person during hemodialysis, or via telephone (based on patient preference). The program is administered by a trained study clinician (occupational therapist or nurse).
Study NCT03825770 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Education about Kidney Disease
Description: General education about kidney disease involves a review of information from the Kidney Foundation of Canada's patient handbooks Living with Reduced Kidney Function and Living with Kidney Failure (www.kidney.ca/manual) during 6-8 brief individual sessions with a trained study clinician (occupational therapist or nurse).The handbooks contains general information about managing kidney disease, addressing topics such as medication management, diet, and emotional well-being on dialysis. Sessions will take place either in person during hemodialysis, or via telephone (based on patient preference).
Study NCT03167996 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of HealthPals (Telemedicine supported by digital health platform)
Description: HealthPals is a smartphone-based chronic disease management mobile application. It uses the mobile health capabilities of smartphones to provide a secure communication portal for patients with their Care Teams to help achieve cardiovascular risk reduction through a digital health coach-based coaching for lifestyle and medication compliance.~The HealthPals app was developed by HealthPals, Inc.
Study NCT00202735 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arm1:Immobilization in external rotation
Description: Immobilization in external rotation (ER) All patients in the ER group use a prefabricated shoulder immobilizer (Don Joy Ultrasling Er,15˚ version).To control the position,a line at the top of the immobilizer is to be parallel with the frontal plane when the arm is correctly placed in 15 degrees of external rotation.
Study NCT00202735 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: immobilization in internal rotation
Description: All the patients in the internal rotation(IR) group are immobilized with their arm/shoulder in internal rotation by using a normal collar and cuff device.
Study NCT03535727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: IV over 30 minutes; Days 4 and 11
Study NCT05826756 — intervention group
Intervention type: OTHER
Intervention: There are no interventions in this study. All participants complete online surveys.
Description: There are no interventions in this study. All participants complete online surveys.
Study NCT02173574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEB025
Study NCT02173574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP239
Study NCT03480100 — intervention group
Intervention type: DRUG
Intervention: Xylometazoline Nasal Spray
Description: Application of Xylometazoline Nasal Spray in accordance with the instructions for use
Study NCT03480100 — intervention group
Intervention type: DEVICE
Intervention: Ectoin Nasal Douche
Description: Application of Ectoin Nasal Douche (END01) in accordance with the instructions for use
Study NCT03029143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab IV
Description: Vedolizumab intravenous infusion.
Study NCT02588976 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Sonoclot Analyzer
Description: Blood coagulation test during cardiac surgery: Measurement of activated clotting time during cardiac surgery by Sonoclot Analyzer
Study NCT02122003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib 400 mg bid
Study NCT00892736 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02348333 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FYU-981, (Oral daily dosing for 7 days)
Description: Subjects randomized to the FYU-981 arm receive active drug, FYU-981.
Study NCT02348333 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, (Oral daily dosing for 7 days)
Description: Subjects randomized to the placebo arm receive placebo.
Study NCT00892736 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00892736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study NCT01462604 — intervention group
Intervention type: OTHER
Intervention: non-drug intervention educational programme
Description: educational programme
Study NCT02254655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Puerarin injection 400 mg
Description: Patients receive treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, statins, bone metabolism regulators and gastric mucosal protective agents on as-needed basis.Furthermore, patients were administrated with 400 mg intravenously infused puerarin injection once a day.Each treatment course lasted for 2 weeks followed by a regular time interval of 15 days.
Study NCT02254655 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Patients receive treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, statins, bone metabolism regulators and gastric mucosal protective agents on as-needed basis
Study NCT02215356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib with concurrent radiotherapy
Description: Icotinib: 125 mg is administered orally three times per day.
Study NCT04441541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill with auditory feedback
Description: Participants will receive training 3 times per week for 4 weeks (12 sessions).
Study NCT04441541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill with visual feedback
Description: Participants will receive training 3 times per week for 4 weeks (12 sessions).
Study NCT04441541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill with auditory and visual feedback
Description: Participants will receive training 3 times per week for 4 weeks (12 sessions).
Study NCT04441541 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill training
Description: Participants will receive training 3 times per week for 4 weeks (12 sessions).
Study NCT02856217 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tunneling
Description: In this arm of the study which is Peritoneal tunneling group in SCP, standard minimal invasive sacrocolpopexy procedure will be performed. Placement of mesh between vaginal apex and sacrum is retroperitoneally (creating a tunnel between vaginal apex and sacrum under peritoneum without disturbing the integrity of the peritoneum)
Study NCT02856217 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: non-tunneling
Description: In this arm of the study which is Peritoneal non-tunneling group in SCP, standard minimal invasive sacrocolpopexy procedure will be performed. Placement of mesh between vaginal apex and sacrum is retroperitoneally (incised and sutured peritoneum between vaginal apex and sacrum).
Study NCT04190888 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention - observational study
Study NCT02014701 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Echocardiogram
Description: 1. Contrast echocardiography with Optison for assessment of regional wall motion. This will be performed immediately following the resting echocardiogram by a sonographer specifically trained in myocardial contrast echocardiography.~2. Contrast echocardiogram with Optison for assessment of myocardial perfusion. This will be performed using a continuous infusion of Optison using low mechanical index power-modulation imaging of the myocardium and blood pool. Myocardial perfusion will be assessed offline using video intensity analysis software.
Study NCT04356651 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fu's subcutaneous needling(FSN)
Description: In this study, physician will use a disposable Fu's subcutaneous needling(FSN) to penetrate the subject's skin from anterior superior iliac spine(ASIS) to 1/3 superior border of patella. Then the physician will push forward the needle parallel to the skin surface. The physician will sway the needle 45 times in 30 seconds. After swaying the needle, the physician will instruct the subject to do sole dorsiflexion for 10 seconds resisting the physician's opposite force, then the subject take a rest for 10 seconds. The above actions are 3 repetitions. Then the subject do knee flexion and extension for 10 seconds, and take a rest for 10 seconds. These actions are also 3 repetitions. After the above reperfusion approach of muscles, the physician will take out the needle to finish the treatment.
Study NCT04356651 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electric Nerve Stimulation
Description: Transcutaneous electrical nerve stimulation (TENSor TNS) is the use of electric current produced by a device to stimulate the nerves for therapeutic purposes. TENS, by definition, covers the complete range of transcutaneously applied currents used for nerve excitation although the term is often used with a more restrictive intent, namely to describe the kind of pulses produced by portable stimulators used to treat pain. The unit is usually connected to the skin using two or more electrodes. A typical battery operated TENS unit is able to modulate pulse width,frequency and intensity. Generally TENS is applied at high frequency (>50 Hz) with an intensity below motor contraction (sensory intensity) or low frequency (\<10Hz) with an intensity that produces motor contraction.
Study NCT03328208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comfort Talk® app
Description: Test app
Study NCT03328208 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: White Noise app
Description: White Noise app built to mimic appearance of Comfort Talk® test app
Study NCT00565461 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: heat-labile enterotoxin of E. coli (LT)
Description: 37.5ug patch applied on either the deltoid or the thigh
Study NCT05304325 — intervention group
Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Sleeve gastrectomy
Study NCT05304325 — intervention group
Intervention type: OTHER
Intervention: Blood sampling
Description: Blood samples will be collected to measure glucose, insulin, albumin, uric acid, HbA1c, lipids, hepatic enzymes, TSH, hs-CRP, complete blood cell counts and persistant organic pollutants
Study NCT05304325 — intervention group
Intervention type: OTHER
Intervention: Blood pressure
Description: Systolic and diastolic blood pressure will be measured.
Study NCT02328365 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured medical follow-up after operation
Description: Patients in the intervention arm are seen by a physician on the 4th or 5th postoperative day before discharge to pick up and manage any medical problems, and are furthermore seen in the cardiology clinic 1 month after operation, and in the pulmonary medicine clinic 1 and 3 months after operation
Study NCT04336501 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IM19 CAR-T
Description: All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later
Study NCT03208296 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASN-002
Description: ASN-002 has been designed for clinical applications, especially for intratumoral administration in the treatment of various cancers. This rAd vector delivers the gene of interest, in the case of ASN-002 the human IFNγ gene, into target cells. The rAd vector in ASN-002 is replication deficient and although it infects cells, it is not able to replicate in the tumor or in normal human cells. The infected cells are able to transcribe and translate the IFNγ DNA leading to a sustained local concentration of IFNγ in the tumor mass that is designed to avoid high levels of systemic IFNγ that may be lead to unacceptable toxicity.
Study NCT03230370 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UFT
Description: The EUEP group receives additional daily 50 mins program focusing on training of the hemiplegic upper extremity,
Study NCT03230370 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LFT
Description: The ELEP group receives additional daily 50 mins program focusing on training of the hemiplegic lower extremity.
Study NCT02074683 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Year A Pathway
Description: Fat Grafting Operative Procedure followed by Standard of Care Follow-up.
Study NCT05304325 — intervention group
Intervention type: OTHER
Intervention: Anthropometric measurements
Description: Body weight, height and waist circumference will be measured.
Study NCT02074683 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Year B Pathway
Description: Standard of Care Followed by Fat Grafting Operative Procedure
Study NCT02614599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP22042013
Description: This group of patients receive 2.000 kilo-calories diet (60 g. carbohydrates, 144 gr of fat and 107 gr of proteins), including 2 protein shakes.
Study NCT02614599 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet
Description: the second group of patients receive diet of 2.000 Kilo-calories without rapidly absorbed carbohydrates and without proteins supplements
Study NCT01980667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lurbinectedin (PM01183)
Description: lurbinectedin (PM01183) is presented as powder for concentrate for solution for infusion with two strengths, 1-mg and 4-mg vials.
Study NCT01980667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: vials containing 1 mg/ml concentrate for solution for infusion
Study NCT05304325 — intervention group
Intervention type: OTHER
Intervention: Body composition
Description: Body composition will be evaluated by dual-energy X-ray absorptiometry.
Study NCT00742144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ofatumumab
Description: Ofatumumab (GSK1841157), a clear colorless liquid, is supplied in a glass vial. Each vial contains 100mg of ofatumumab in 5mL.
Study NCT05304325 — intervention group
Intervention type: OTHER
Intervention: Resting metabolic rate
Description: Resting metabolic rate will be measured by indirect calorimetry.
Study NCT05304325 — intervention group
Intervention type: OTHER
Intervention: Food intake
Description: Food intake, energy intake and food quality will be evaluated using the food frequence questionnaire.
Study NCT02722304 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARALAST NP 60 mg/kg
Description: ARALAST NP is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy
Study NCT02722304 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARALAST NP 120 mg/kg
Description: ARALAST NP is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy
Study NCT02722304 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLASSIA 60 mg/kg
Description: GLASSIA is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy
Study NCT02722304 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLASSIA 120 mg/kg
Description: GLASSIA is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy
Study NCT02722304 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Human Albumin 2%
Description: Human albumin 2% (by appropriate dilution with normal saline solution)
Study NCT05304325 — intervention group
Intervention type: PROCEDURE
Intervention: Adipose tissue biopsy
Description: A sample of 3-5g of adipose tissue will be collected under local anesthesia by needle aspiration in the periumbilical region.
Study NCT02215356 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemoradiotherapy
Description: Etoposide 50mg/m2, ivgtt, d1-d5; cisplatin 50mg/m2, ivgtt, d1 and d8, every 28 days for a cycle, a total of 2 cycles
Study NCT02615639 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPDC-T cells & Entecavir
Description: experimental groups will be given HPDC-T cells \& Entecavir. HPDC-T cells will be given for 24weeks on the basis of anti-HBV therapy ,and entecavir 0.5mg tablet every night by mouth
Study NCT02615639 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: 0.5mg tablet every night by mouth
Study NCT00958074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given PO
Study NCT02615639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPDC-T cells & IFN-a-2a
Description: experimental groups will be given HPDC-T cells \& IFN-a-2a. HPDC-T cells will be given for 24 weeks on the basis of anti-HBV therapy ,and IFN-a-2a 180ug subcutaneous injection every week
Study NCT00958074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: correlative study
Study NCT02615639 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IFN-a-2a
Description: IFN-a-2a 180ug subcutaneous injection every week
Study NCT02615639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPDC-T cells & Telbivudine
Description: experimental groups will be given HPDC-T cells \& Telbivudine. HPDC-T cells will be given for 24weeks on the basis of anti-HBV therapy ,and Telbivudine 600mg tablet every day by mouth
Study NCT02615639 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telbivudine
Description: Telbivudine 600mg tablet every day by mouth
Study NCT01545505 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neuropsychological assessment
Description: A clinical evaluation with Impact of Events Scale-Revised, Child Post-Traumatic Stress Reaction Index, State-Trait Anxiety Inventory for Children, Children Depression Inventory and Emotion, activity and sociability.~A neuropsychological assessment with a emotional Go-No/Go, a visual search task, the Trail Making Test, 3 items of the WISC III ( and the Grober and Buschke Test.
Study NCT04928859 — intervention group
Intervention type: DRUG
Intervention: Albumin
Description: At least one dose of human albumin was used for the patients during hospitalization in the burn ward consisted the albumin group.~The patients who have no albumin use during their hospitalization in the burn ward consisted the control group.
Study NCT00958074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: correlative study
Study NCT04345224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic tape
Description: A kinesiology tape will be applied to the lateral hip of the affected side to facilitate the gluteus medius muscle activation while the participant is lying down. The first third of one I-strip will begin at the posterior iliac crest without tension to provide an anchor that will not cross the target tissue. The participant will actively flex the adducted hip to allow for the application of the middle third of the tape with approximately 50 percent tension (able to visualize the wave pattern in the tape). Subsequently, with the leg in the original position, the remainder of the tape will be applied without tension, ending approximately at the greater trochanter. Afterward, the second I-strip will be applied in the same manner starting at the anterior iliac crest.
Study NCT01537562 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Timing of IUC insertion
Description: Patients randomised to early insertion had their IUC inserted on day 5-9 after mifepristone treatment while patients randomised to delayed insertion had the IUC insertion at about 3 to 4 weeks after mifepristone.